Trial Profile
An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Beta-thalassaemia
- Focus Pharmacokinetics
- Sponsors Novartis
- 10 Sep 2014 New trial record